Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the ...

Replimune Group (NASDAQ:REPL – Get Free Report) had its price target raised by investment analysts at BMO Capital Markets ...

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price shot up 6% during trading on Wednesday after BMO Capital Markets raised their price target on the stock from $18.00 to $27.00.

WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.

Replimune Group Inc has established itself as a leader in the field of oncolytic immunotherapy, with a wholly-owned pipeline and advanced manufacturing facilities. The company's primary focus is on ...

Replimune Group Inc is focused on developing novel oncolytic immunotherapies for the treatment of various cancers. The company's lead product candidate, RP1, is being developed for the treatment of ...